| Not Yet Recruiting | Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD NCT07435129 | Scholar Rock, Inc. | Phase 2 |
| Recruiting | A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD NCT07038200 | Avidity Biosciences, Inc. | Phase 3 |
| Recruiting | A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy NCT06907875 | Epicrispr Biotechnologies, Inc. | Phase 1 / Phase 2 |
| Recruiting | Personalized Training for People With Rare Neuromuscular Disorders NCT06708468 | Oslo University Hospital | N/A |
| Recruiting | BetterLife FSHD: A Patient-driven Health and Research Platform NCT07409142 | FSHD Society | — |
| Completed | Quantitative Assessment of Orofacial Muscle Function in FSHD NCT06425445 | University of Mons | N/A |
| Unknown | Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics NCT06086548 | University Hospital, Angers | — |
| Completed | Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity Findings NCT07331025 | Koç University | — |
| Active Not Recruiting | ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot Study NCT05453461 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia) NCT05178706 | Istanbul University - Cerrahpasa | — |
| Terminated | Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dys NCT03943290 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Active Not Recruiting | Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD NCT03458832 | University of Kansas Medical Center | — |
| Completed | Study of Testosterone and rHGH in FSHD NCT03123913 | University of Rochester | Phase 1 |
| Completed | Arm Cycling in Facioscapulohumeral Dystrophy (FSHD) Patients NCT04267354 | Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust | N/A |
| Terminated | Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) NCT02927080 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Completed | Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With NCT02836418 | aTyr Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Rasch-analysis of Clinical Severity in FSHD NCT02766985 | University of Kansas Medical Center | — |
| Completed | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LG NCT02579239 | aTyr Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Facioscapulohumeral Dystrophy in Children NCT02625662 | University Medical Center Nijmegen | — |
| Completed | Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy NCT02531217 | aTyr Pharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Biomarker Development for Muscular Dystrophies NCT05019625 | Massachusetts General Hospital | — |
| Completed | Bone Health in Facioscapulohumeral Muscular Dystrophy NCT02413190 | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | — |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Recruiting | The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry NCT04001582 | Newcastle University | — |
| Completed | A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infan NCT01437345 | Cooperative International Neuromuscular Research Group | — |
| Active Not Recruiting | Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy NCT01671865 | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | — |
| Completed | Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD) NCT01596803 | University Hospital, Montpellier | N/A |
| Completed | Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patient NCT00821548 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Study Evaluating MYO-029 in Adult Muscular Dystrophy NCT00104078 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 / Phase 2 |
| Recruiting | Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry NCT00082108 | University of Rochester | — |